Cerity Partners LLC Has $303,000 Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Cerity Partners LLC lifted its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 24.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 302,505 shares of the company’s stock after buying an additional 58,597 shares during the quarter. Cerity Partners LLC owned about 0.19% of Neumora Therapeutics worth $303,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lunate Capital Ltd acquired a new stake in shares of Neumora Therapeutics during the first quarter worth $2,124,000. Swiss National Bank acquired a new stake in shares of Neumora Therapeutics during the fourth quarter worth $1,168,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Neumora Therapeutics by 273.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company’s stock worth $5,523,000 after buying an additional 381,676 shares in the last quarter. Capital International Investors increased its position in shares of Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock worth $39,224,000 after purchasing an additional 3,233,179 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in shares of Neumora Therapeutics in the fourth quarter worth $1,258,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Stock Up 2.6%

Neumora Therapeutics stock opened at $2.35 on Monday. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $17.19. The business’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.20. The stock has a market cap of $380.11 million, a PE ratio of -1.46 and a beta of 2.75.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). As a group, analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Mizuho raised their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Finally, Bank of America restated an “underperform” rating and issued a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.14.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.